Search clinical trials for: Tiotropium + Olodaterol

Total 436 results

Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma

Pulmonary Disease, Chronic Obstructive | Asthma

Netherlands, Germany, Belgium, France, Canada, Italy, South Africa, Denmark
GlaxoSmithKline

Completed

Effect of GSK1160724 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study II)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Terminated

Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation

Pulmonary Disease, Chronic Obstructive
Novartis

Completed

Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.

COPD

Denmark
Boehringer Ingelheim

Completed

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

Pulmonary Disease, Chronic Obstructive

Canada, Germany, United States, Australia
National University of Malaysia

Completed

Tiotropium Respimat Administration With and Without Aerochamber Disease (COPD)

Chronic Obstructive Pulmonary Disease

Malaysia
Boehringer Ingelheim

Completed

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Dose Finding Study in COPD

Pulmonary Disease, Chronic Obstructive

Netherlands, Belgium, United States
University of Crete

Completed

Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients

Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals

Completed

Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation

Chronic Obstructive Pulmonary Disease (COPD)

Colombia, India, Korea, Republic of, Poland, Croatia, Estonia, Hungary, United Kingdom, Israel, Latvia, Turkey, Argentina, Panama, Mexico, Russian Federation, Serbia, Slovenia
National Institute of Respiratory Diseases, Mexico

Completed

Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD) (EMERAL)

COPD

Mexico
Boehringer Ingelheim

Completed

Mechanisms of Dyspnea Relief During Exercise in COPD Patients Following Treatment With Tiotropium (Spiriva)

Pulmonary Disease, Chronic Obstructive

Canada
Boehringer Ingelheim

Completed

High Dose Trial in COPD

Pulmonary Disease, Chronic Obstructive

United States
Tanta University

Completed

Three Treatment of Chronic Obstructive Pulmonary Disease Patients

COPD
Neutec Ar-Ge San ve Tic A.Ş

Completed

Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment

COPD

Turkey
Boehringer Ingelheim

Completed

A Double-blind, Randomised Study to Assess the Influence of Tiotropium (Spiriva®)

Healthy

Germany
Chinese University of Hong Kong
Hoffmann-La Roche

Completed

A Study on Higher-dose Oseltamivir Treatment's Impact on Viral Clearance and Clinical Recovery in Adults Hospitalized With Influenza

Respiratory Tract Infections | Influenza

Hong Kong
Boehringer Ingelheim

Completed

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
University of Saskatchewan

Completed

Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses

Allergic Asthma

Canada
Boehringer Ingelheim

Completed

Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Russian Federation, Spain, Bulgaria, Canada, Hungary, Argentina
Novartis Pharmaceuticals

Completed

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients (FAVOR)

Chronic Obstructive Pulmonary Disease | COPD

Germany
Novartis Pharmaceuticals

Completed

Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients (INHALATOR)

Chronic Obstructive Pulmonary Disease (COPD)

Brazil
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Boehringer Ingelheim

Completed

Tiotropium Bromide in Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Switzerland, United Kingdom
Boehringer Ingelheim

Completed

Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal).

Pulmonary Disease, Chronic Obstructive

Portugal
Sunovion

Completed

Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Emphysema | Bronchitis

United States
Novartis Pharmaceuticals

Completed

Efficacy, Tolerability and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Australia, New Zealand
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma II

Asthma

United States, Brazil, China, Colombia, Germany, India, Japan, Mexico, Peru, Poland, Romania
Nephron Pharmaceuticals Corporation
Rho, Inc.

Completed

Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease (COPD)

United States
University of Alberta

Withdrawn

Tiotropium for Smoking Asthmatics Study

Asthma

Canada
Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD

Chronic Obstructive Pulmonary Disease

Brazil
Gelb, Arthur F., M.D.
Pfizer; Boehringer Ingelheim

Completed

Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema

Emphysema | COPD

United States
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD

Pulmonary Disease, Chronic Obstructive

United States, Canada
University of Dundee
Tenovus Scotland

Completed

Ultra-long Acting Bronchodilator Therapy in Asthmatics (MAN02)

Asthma

United Kingdom
Boehringer Ingelheim

Completed

Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1

Pulmonary Disease, Chronic Obstructive

United States, Puerto Rico
GlaxoSmithKline

Completed

Safety Study Using GSK233705 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Germany
Novartis Pharmaceuticals

Completed

Effect of Indacaterol on Inspiratory Capacity (IC)

Chronic Obstructive Pulmonary Disease

Germany
ThomasTruncale
Boehringer Ingelheim

Completed

The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease | Chronic Bronchitis

United States
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)

Asthma

United States, Australia, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Serbia, South Africa, Turkey, Ukraine, United Kingdom
Boehringer Ingelheim
Pfizer

Completed

Evaluation of Tiotropium 2.5 and 5 µg Once Daily Delivered Via the Respimat Inhaler Compared to Placebo in Patient With Moderate to Severe Persistent Asthma

Asthma

Japan
Boehringer Ingelheim

Completed

Tiotropium / Respimat One-Year Study

Pulmonary Disease, Chronic Obstructive

Germany, Canada, Spain, Russian Federation, United States, Belgium, France, Greece, Sweden, Norway, Turkey, Australia, Netherlands, United Kingdom
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands

3

Subscribe